Reduced degeneration of an axon predetermined to be subject to
degenerative neuropathy in a term patient is effected by contacting the
axon in situ with an effective amount of a ubiquitin-proteasome system
(UPS) inhibitor sufficient to reduce degeneration of the axon; and
detecting a resultant reduction in the degeneration of the axon in situ.
